Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load

AIDS

Volumn 25, Issue 10, 2011, Pages 1332-1333

  De Wit, Stéphane ^a   Delforge, Marc ^a   Necsoi, Coca Valentina ^a   Clumeck, Nathan ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD38 ANTIGEN; CD4 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ANTIGEN FUNCTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS LOAD;

ANTIGENS, CD38; CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; FEMALE; HEPTANOIC ACIDS; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; PYRROLES; VIRAL LOAD;

EID: 79958779542     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347c083     Document Type: Article

References (10)

1. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2010. [Epub ahead of print]
2. Langford S, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007. doi: 10.1186/1742-6405-11.
3. Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002; 13:1673-1681. (Pubitemid 34579257)
4. Blanco-Coli LM, Tunon J, Martin-Ventura JL, Egido J. Antiin-fammatory and immunomodulatory effects of statins. Kidney Int 2003; 63:12-23.
5. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-1402. (Pubitemid 32001026)
6. Weitz-Scmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Burns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-692. (Pubitemid 32588024)
7. Bayerle-Eder M, Fuchsjager-Mayrl G, Sieder A, Polska E, Roden M, Stulnig T, et al. Effect of pravastatin on responsiveness to N-monomethyl-L-argimine in patients with hypercholesterolae-mia. Atherosclerosis 2002; 160:177-184. (Pubitemid 34076653)
8. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175:83-90. (Pubitemid 38746913)
9. Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but inflammatory markers in ACTG 5087. J Clin Lipidol 2010; 4:279-287.
10. Lefèvre C, Auclair M, Boccara F, Bastard JP, Capeau J, Vigouroux C, Caron-Debarle M. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30:2611-2620.